Combinational studies of BOLD-100/KP1339 with established chemotherapeutics in gastrointestinal multicellular tumor spheroids
Dominik Wenisch, Slavica Ždravac, Michael A Jakupec, Franz Jirsa, Bernhard K Keppler · 2026
Read Combinational studies of BOLD-100/KP1339 with established chemotherapeutics in gastrointestinal multicellular tumor spheroids by Dominik Wenisch, Slavica Ždravac, Michael A Jakupec, Franz Jirsa, Bernhard K Keppler (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13197383.txt.
Description
Dominik Wenisch and co-authors present a 2026 lab study pairing an experimental metal drug with standard chemotherapy against gut cancers. The drug, a ruthenium compound called BOLD-100, attacks a protein-folding helper inside cells rather than DNA, unlike platinum drugs. Blocking that helper can push stressed cancer cells toward death.
The team grew stomach and bowel cancer cells as small three-dimensional balls, which mimic real tumours better than flat layers. They tested the new drug alone and with four standard partners. The point was to see which pairs beat single drugs before patient trials lean on such mixes. The work ties into an ongoing clinical trial in the same cancers.
Catalog record
| CREATOR | Dominik Wenisch, Slavica Ždravac, Michael A Jakupec, Franz Jirsa, Bernhard K Keppler |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |